(Q37914103)

25 August 2017

title

The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine (English)

1 reference

25 August 2017

0 references

0 references

Ruiling Zhang

1

1 reference

25 August 2017

Wei Hao

2

1 reference

25 August 2017

Miao Pan

3

1 reference

25 August 2017

Chuansheng Wang

4

1 reference

25 August 2017

Xiuli Zhang

5

1 reference

25 August 2017

Da Chun Chen

6

1 reference

25 August 2017

Mei Hong Xiu

7

1 reference

25 August 2017

Fu De Yang

8

1 reference

25 August 2017

Thomas R Kosten

9

1 reference

25 August 2017

Xiang Yang Zhang

10

1 reference

25 August 2017

publication date

8 August 2011

1 reference

25 August 2017

published in

Human Psychopharmacology

1 reference

25 August 2017

volume

26

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

392-396

1 reference

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

25 August 2017

cites work

1 reference

Relationship of atypical antipsychotics with development of diabetes mellitus

21 January 2018

1 reference

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

21 January 2018

1 reference

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

Clozapine-associated diabetes

21 January 2018

1 reference

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

21 January 2018

1 reference

Genomics, type 2 diabetes, and obesity

21 January 2018

1 reference

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

21 January 2018

1 reference

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

21 January 2018

1 reference

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

21 January 2018

1 reference

Clozapine use and risk of diabetes mellitus

21 January 2018

1 reference

The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.

21 January 2018

1 reference

A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States

21 January 2018

1 reference

7 January 2021

The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.

1 reference

7 January 2021

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

7 January 2021

Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates

1 reference

7 January 2021

Family history of type 2 diabetes in schizophrenic patients

1 reference

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1220

1 reference

25 August 2017

1 reference